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The objective of the current study was the development of a simple, rapid, and accurate isocratic reverse-phase ultra-performance
liquid chromatographic (RP-UPLC) method for the routine control analysis of imipramine hydrochloride (IMH) in bulk drug and
in pharmaceutical formulations.This work was carried out in order to reduce analysis time and maintaining good efficiency which
in turn is focused on high-speed chromatographic separations.Themethod was developed usingWaters Acquity BEH C18 column
(100mm × 2.1mm, 1.7 𝜇m)withmobile phase consisting of a mixture of acetonitrile and ammonium acetate buffer of pH-5 (80 : 20,
v/v/v). UV detectionwas performed at 220 nm for eluted compound. An excellent linearity was observed in the concentration range
0.2–3 𝜇g/mL IMH with a regression coefficient (𝑟2) value of 0.9999. The method developed was validated and forced degradation
was performed as per ICH guidelines. The limit of detection (𝑆/𝑁 = 3) was 0.2532 ng/mL and the limit of quantitation (𝑆/𝑁 = 10)
was found to be 0.7672 ng/mL. The drug IMH was subjected to hydrolytic, acidic, basic, thermal, photolytic, and oxidative stress
conditions according to ICH regulations. IMH was found to be stable in basic, thermal, and photolytic conditions and degrades in
acidic, hydrolytic, and oxidative stress conditions.
1. Introduction
Imipramine hydrochloride (IMH) is a tricyclic antide-
pressant. It is a dibenzazepine derivative and chemically
IMH is 3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl) propy-
ldimethylamine hydrochloride (Figure 1). IMH is commonly
used to treat the depressive disorders owing to their efficiency
in elevating the mood of patients by interfering to the
reuptake of norepinephrine or serotonin [1]. The drug is
official in European Pharmacopoeia [2].
The literature on the methods for the determination
of IMH is vast. Several analytical methods have been
reported for the determination of IMH in biological fluids
and/or pharmaceutical formulations. These include chro-
matographic techniques like HPLC [3–9], TLC [10], GC [11–
14], LC with direct injection and electrochemical detection
[15], adsorptive stripping voltammetry [16], chemometric
methods [17], flow-injection extraction spectrophotometry
[18], derivative spectrophotometry [19, 20], and visible spec-
trophotometry [20–24].
Many of the reported methods for the determination of
imipramine suffer from one or the other disadvantages like
time consuming and require expensive experimental setup
[11–14], and chemometric methods are less sensitive [17].
Besides, the reported spectrophotometric methods are less
sensitive [18–24] and require extraction procedures [23] and
costly chromogenic reagent [24] (Table 1). Considering these
demerits, there was a need to develop a more advantageous
chromatographic method for the determination of IMH in
bulk sample and in tablets.
To our present knowledge, no validated stability indicat-
ing UPLC assay method for the determination of IMH in
pharmaceutical formulation was available in the literature.
Though the numbers of liquid [3–9], thin layer [10], gas
chromatographic methods [11–14], and LC with direct injec-
tion and electrochemical detection [15] have been reported




Figure 1: Structure of imipramine hydrochloride.
earlier for IMH, no attempt has been made to apply this
new type of ultra performance liquid chromatography for its
determination in pharmaceuticals.
The present work deals with a stability-indicating
RP-UPLC method for the quantitative determination
of imipramine HCl in bulk and in tablets. This method
was successfully validated according to the International
Conference Harmonization (ICH) guidelines [25].
2. Experimental
2.1. Chemicals and Reagents. Pharmaceutical grade IMH
(purity ≥ 98.9%) was supplied by Cipla India Ltd., Mumbai,
India, as a gift sample and was used as received. Pharma-
ceutical formulations of IMH such as imipramine (Sun) and
Depranil (La Pharma) samples were purchased from local
markets. HPLC grade acetonitrile was purchased from RCl
Labscan, Hyderabad, India. Water HPLC grade was obtained
from a Milli-Q water purification system, Bedford, USA.
Analytical grade ammonium acetate and 80% phosphoric
acid were obtained from Ranbaxy Fine Chemicals, New
Delhi, India.
2.2. Buffer Preparation. Solution of ammonium acetate
(0.08M) was prepared by dissolving 0.6167 g of ammonium
acetate in one litre of water. The pH of this solution was
adjusted to 5.0 with phosphoric acid. The buffer solution was
found stable with respect to pH and visual clarity for 48 h.
2.3. Ultra-Performance Liquid Chromatographic Conditions.
UPLC analysis was carried out on a Waters Acquity UPLC
system (Waters, Manchester, UK). The output signal was
monitored and processed using Empower-2 software. The
chromatographic column used was Acquity BEH column (C-
18 100mm, 2.1mm, and 1.7 𝜇m; Waters, Manchester, UK)
equipped with binary solvent delivery pump, autosampler,
and tunable UV (TUV) detector. The solvent contains a
mixture of 0.08M ammonium acetate buffer and acetonitrile
in the ratio 20 : 80 (v/v/v). Total cycle time was 6min with a
flow rate of 0.3mL/min and an injection volume of 2 𝜇L using
partial loop mode. The isocratic flow rate of mobile phase
was maintained at 0.3mL/min. The column temperature was
adjusted to 25∘C. The sample run was monitored at 220 nm
and the run time was 6.0min. The retention time of the
sample was observed at about 2.0min.
2.4. Preparation of Stock Solution. A stock standard solution
equivalent to 100𝜇g/mL of IMH was prepared by dissolving
accuratelyweighed 10mgof pure IMH in a 100mLvolumetric
flask and diluted to mark with the mobile phase and filtered
through a 0.22𝜇m nylon membrane filter. Working solutions
were prepared as required by dilution with the same solvent
and the solution obtained was analyzed by UPLC.
2.5. Preparation of Sample Solution. For the preparation of
IMH solution, IMH tablet samples such as imipramine and
Depranil were purchased from local markets. 10mg of finely
pulverized tablets was accurately weighed and transferred to
a 100mL volumetric flask. To this 20mL of mobile phase ace-
tonitrile, ammonium acetate buffer, (80 : 20, v/v) was added
and the mixture was sonicated, and the volume was diluted
to the mark with mobile phase to yield a concentration of
100 𝜇g/mL. Working solutions were prepared as required
by dilution with the same solvent and the samples were
filtered through a 0.22𝜇mnylon membrane filter prior to the
injection into UPLC system.
2.6. Stress Studies. Forced degradation studies were carried
out for imipramine to provide an indication of the stability
indicating property and specificity of the proposed method.
Forced degradation of drug substances was carried out under
acidic, basic, neutral, oxidative, photolytic, and thermal stress
conditions.
2.6.1. Acid Hydrolysis. For acid decomposition studies, IMH
bulk sample was dissolved in 0.1M HCl at a concentration
of 1 𝜇g/mL and the solution was heated at 80∘C for a period
of 6 h. Before carrying out the UPLC analysis, samples were
suitably diluted and neutralized with 0.1 N NaOH.
2.6.2. Base Hydrolysis. The studies in alkaline conditions
were done in 0.1M NaOH at a concentration of 1 𝜇g/mL and
the solution was heated at 80∘C for a period of 6 h. Before
carrying out theUPLC analysis, samples were suitably diluted
and neutralized with 0.1 N HCl.
2.6.3. Oxidation. Hydrogen peroxide was utilized for the
oxidative degradation study. The drug substance was treated
with 5% hydrogen peroxide solution at 80∘C for a period of
6 h.
2.6.4. Thermal Degradation Studies. To investigate the sus-
ceptibility of the drug under thermal stress conditions, the
drug was spread in a borosilicate glass petri dish and placed
in the hot-air oven maintained at 80∘C for 24 h.
2.6.5. Photolytic Degradation Studies. Photodegradation
studies were carried out by exposing the drug in solution
(1 𝜇g/mL) and solid state (powder) drug in a photostability
chamber for 10 days. The samples of both solution and
powder were kept in parallel in darkness (wrapped) for
the same period. Samples were withdrawn after 24 h and
analyzed.
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Table 1: Comparison of the performance characteristics of the proposed method with some of the existing chromatographic/spectrophoto-
metric methods.
Sl No. Reagent/s used Methodology Linear range Remarks References
1 NaClO4—buffer ethanol Derivative spectrophotometry 0.62–10.14 𝜇g/mL
Sensitive but lack of
selectivity [19]
2 Methyl orange
Formation of ion pair with
methyl orange and the
absorbance was measured at
425 nm
0.79–25.3 𝜇g/mL Less sensitive [21]
3 Eriochrome cyanine R
Reacts in neutral medium with
imipramine forming reddish
compound
10–80𝜇g/mL Less sensitive and hasnarrow range [22]
4 Iminodibenzylp-chloranilic acid
First derivative of ratio spectra



























maximum absorption at 630 nm
1.0–25𝜇g/mL
(C = 3.20 × 103) Less sensitive [24]
7
Mobile phase consisting of a
mixture of acetonitrile and
ammonium acetate buffer of
pH-5 (30 : 30 : 40, v/v/v)
UPLC 0.2–3 𝜇g/mL Highly sensitive andselective Developed method
Table 2: System suitability data.
Property Mean ± SD,
(𝑛 = 6)
RSD (%) Required limits
Retention time (Rt) 2.22 ± 0.01 0.32 RSD ≤ 2%
Tailing factor (T) 1.12 ± 0.008 0.95 𝑇 ≤ 2
Theoretical plates (N), 2979 ± 55 1.11 𝑁 > 2000
Capacity factor (k) 1.198 ± 0.005 0.44 —
2.7. Method Validation
2.7.1. Linearity and Range. To establish linearity, eight point
calibration standards of the following concentrations 0.2, 0.5,
1.0, 1.5, 2.0, and 3.0 𝜇g/mL were prepared; three indepen-
dent determinations were performed at each concentration.
Aliquots of 2.0 𝜇L were injected in triplicate (six injections)
and eluted with the mobile phase under the reported chro-
matographic conditions. Calibration curve was constructed
by plotting the concentration of IMH versus corresponding
mean peak area.The correlation coefficient (𝑟2), slope (𝑏), and
intercept (𝑎) of the calibration curve were calculated.
2.7.2. Accuracy. Accuracy was evaluated as percentage rela-
tive error (%RE) between themeasuredmean concentrations
and taken concentrations. Pure IMH solutions at three differ-
ent concentrations were analyzed in six replicates during the
same day (intraday) and on three different days (interday).
Table 3: Linearity and regression parameters with precision data.
Parameter Value
Linear range in 𝜇g/mL 0.2–3.0
Limits of quantification (LOQ) ng/mL 0.7672




Correlation coefficient (𝑟2) 0.9997
Standard deviation of 𝑏, (𝑆
𝑏
) 1980.26
Standard deviation of 𝑎, (𝑆
𝑎
) 5214.63
Further the accuracy of the proposed method is con-
firmed by performing recovery experiments by standard
addition technique.The accuracy of themethod for IMHwas
evaluated in triplicate (𝑛 = 3) by adding three concentrations
of 0.5, 1.0, and 1.5 𝜇g/mL (50%, 100%, and 150%) of the pure
drug to the preanalyzed formulations and the recovery was
calculated.
2.7.3. Precision. The precision of the method was determined
using six independent test solutions. Inter- and intraday
variation and analyst variation were studied to determine
the intermediate precision of the proposed method. Six
injections of three different concentrations (0.5, 1.0, and
























Figure 2: Typical chromatogram of (a) IMH (10 𝜇g/mL); (b) blank.





found in 𝜇g/mL RE %
Concentration of IMH
found in 𝜇g/mL RE %
0.5 0.495 1.07 0.502 −0.47
1 0.972 2.82 1.031 −3.07





















2.0 𝜇g/mL) were given on the same day (intraday) and the
values of relative standard deviation (RSD) were calculated
to determine intraday precision. The same protocol was
followed for three different days to study interday variation
(𝑛 = 3).
2.7.4. Sensitivity. Sensitivity of the method was proved by
establishing the limits of detection (LOD) and quantitation
(LOQ) for IMH in pure and in dosage forms. The LOD and
LOQ for IMH were determined at a signal-to-noise ratio
of 3 : 1 and 10 : 1, respectively, by injecting a series of dilute
solutions with known concentrations. Precision study was
also carried out at the LOQ level by injecting six (𝑛 = 6)
individual preparations and calculating the % RSD for the
obtained peak area for IMH.
2.7.5. Robustness and Ruggedness. The robustness of an ana-
lytical procedure is a measure of its capacity to remain
unaffected by small, but deliberate variations in method
parameters and provides an indication of its reliability during
normal usage. The factors chosen for this study which were
critical sources of variability in the operating procedures
such as mobile phase pH (±0.5), temperature of the column
(±5∘C), flow rate (±0.05mL/min), mobile phase composition
(70 : 30, 75 : 25, and 85 : 15; buffer : solvent, v/v), and detection
wavelength (220 ± 2 nm) were the varied parameters. To
determine the ruggedness of the method, three different
columns of the same dimensions were used for the analyses.
The study was performed in the same day and three different
days by three different analysts for three different concentra-
tions of IMH (triplicate injections).
2.7.6. Stability of Solution and Mobile Phase. Stability of
IMH working solution was established by storage of sample
solution at ambient temperature for 24 h. Sample solution
was reanalyzed after 24 h and assay was determined and
compared against fresh sample. The mobile phase study
was demonstrated by injecting the freshly prepared sample
solution at different time intervals (0, 12, and 24 hours) and
RSD values of the peak areas were calculated.
3. Results and Discussion
3.1. Method Development and Optimization. The UPLC pro-
cedure was optimized with a view to developing a method
for stability-indicating assay. In order to get good chromato-
graphic results and better retention times, the parameters






































































Figure 4: (a) Acid degradation, (b) base degradation, (c) oxidative degradation, (d) thermal degradation, and (e) photodegradation.
Table 5: Results of the precision study (𝑛 = 5) by the proposed method.
Concentration of IMH
injected in 𝜇g/mL
Intraday precision Interday precision
Mean area ± SD % RSDa Mean area ± SD % RSDa
0.5 79292 ± 30.04 0.0379 79289 ± 37.58 0.0474
1 147141 ± 50.033 0.0342 147151 ± 55.08 0.0374
2 305505 ± 95.04 0.0311 226543 ± 60.83 0.0269
aRelative standard deviation based on peak area.
























Figure 5: (a) Chromatogram of tablet extract; (b) chromatogram of placebo blank.
Table 6: Method robustness.
Condition Modification Mean peakarea ± SD∗ % RSD Mean Rt ± SD % RSD
Mean theoretical
plates ± SD∗ % RSD
Mean tailing
factor ± SD % RSD
Temperature (∘C)
20 147204 ± 105.0 0.88 2.01 ± 0.01 0.55 2976 ± 43 1.43 1.101 ± 0.004 0.35
25 147271 ± 157.2 1.09 2.12 ± 0.02 0.72 3067 ± 59 1.94 1.117 ± 0.003 0.23
30 147144 ± 156.3 1.52 1.99 ± 0.01 0.33 3119 ± 64 2.07 1.108 ± 0.003 0.24
Mobile phase
composition
70 : 30 147371 ± 147.3 0.84 2.01 ± 0.01 0.57 2979 ± 28 0.96 1.020 ± 0.003 0.29
75 : 25 147304 ± 260.8 1.32 2.12 ± 0.01 0.47 3040 ± 52 1.68 1.110 ± 0.001 0.32
85 : 15 147511 ± 295.1 1.68 2.00 ± 0.01 0.36 3119 ± 65 2.07 1.050 ± 0.007 0.67
Flow rate
0.25 147307 ± 110.15 0.63 1.99 ± 0.004 0.23 3079 ± 12 0.39 1.110 ± 0.004 0.36
0.30 147171 ± 163.7 0.42 2.11 ± 0.005 0.24 3104 ± 8 0.16 1.110 ± 0.004 0.34
0.35 147211 ± 110.00 0.76 2.11 ± 0.0606 0.26 3129 ± 12 0.41 1.108 ± 0.003 0.28
Wavelength
218 nm 147341 ± 163.71 0.34 2.12 ± 0.003 0.14 3019 ± 24 0.81 1.124 ± 0.005 0.45
220 nm 147218 ± 215.48 0.38 2.11 ± 0.003 0.12 3169 ± 26 0.84 1.117 ± 0.003 0.23
222 nm 147254 ± 58.59 0.48 2.12 ± 0.004 0.17 3153 ± 30 0.95 1.106 ± 0.005 0.46
∗Mean value of three determinations.
such as mobile phase composition, column, column tem-
perature, wavelength of detection, pH of mobile phase, and
diluents were optimized. The chromatographic conditions,
especially the composition of mobile phase, could affect
the separation. Therefore, the optimization of mobile phase
components was critical. Of the several solvents and solvent
mixtures investigated acetonitrile, and ammonium acetate
buffer of pH-5 (80 : 20, v/v) was found to produce fine
sharp, well-defined peaks with very good separation and
low retention time (2.0min). Alternative combinations of
gradient and isocraticmethodswere also performed to obtain
a suitable peak. Finally, the isocratic method was found to be
suitable for the assay.
The chromatographic separation was achieved on
Acquity BEH C18, 100mm × 2.1mm, 1.7 𝜇m column
maintained at ambient temperature.The feasibility of various
mixture(s) of solvents such as acetonitrile and ammonium
acetate buffer with pH of 5, along with flow rates 0.3mL/min,
was tested for complete chromatographic resolution of the
IMH. Using the mentioned chromatographic conditions,
well-resolved sharp peak was obtained at retention time of
2min for IMH.
Attempts were made with gradient elution with sol-
vent (ammonium acetate buffer, acetonitrile, and methanol)
using phenyl 50mm × 2.1mm, 2𝜇m, column. However, in
the above column and intended experimental conditions,
columns ended with inconsistent retention time and peak
fronting. The peak eluted before 1.5 minutes with a tailing
factor of 2, when Acquity BEH C18, 100mm × 2.1mm,
1.7 𝜇m column was used for the elution. However, verified
other buffer solutions like (citric acid/sodium citrate; sodium
acetate/acetic acid; disodium hydrogen phthalate/sodium
dihydrogen orthophosphate); column oven temperature is
also studied at room temperature 25∘C; in view of possible
interference study, attempts were also made by adjusting the
mobile phase flow rate. However, no significant impact is
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Table 7: Method ruggedness.
Variable Mean peakarea ± SD∗ % RSD Mean Rt ± SD % RSD
Mean theoretical
plates ± SD∗ % RSD
Mean tailing
factor ± SD % RSD
Analyte (𝑛 = 3) 147474 ± 151.74 0.103 2.128 ± 0.006 0.28 2938 ± 73 2.48 1.13 ± 0.004 0.311
Column (𝑛 = 3) 147547 ± 195.53 0.133 2.129 ± 0.006 0.30 2875 ± 81 2.81 1.15 ± 0.008 0.73
∗Mean value of three determinations.
Table 8: Summary of forced degradation results.
Degradation condition Time Drug decomposed (%)∗ % of drug remainingafter degradation∗ Remarks
HCl 1M at 80∘C 6h 19.98 80.02 Degradation
NaOH 1M at 80∘C 6h 10.55 89.45 Degradation
Water hydrolysis (80∘C) 6 h 0.98 99.02 No degradation
Oxidation by H2O2 (5%), 80
∘C 6h 13.13 86.9 Degradation
Thermal solid, 80∘C 24 h 1.09 98.91 Negligible degradation
UV at 220 nm
Kept in a
photostability
chamber for 10 days
1.42 98.58 Negligible degradation
∗Mean value of three replicates.
observed on the critical chromatographic parameters. Use
of ion pair reagents also did not yield the expected peak.
At 80 : 20 ratio of the mobile phase in the linear gradient
program, a perfect peak was eluted. Thus, the mobile phase
ratio was fixed at 80 : 20 (acetonitrile : buffer) in an isocratic
mobile phase flow rate. The typical chromatograms obtained
for blank and pure IMHs from final UPLC conditions are
depicted in Figure 2.
3.2. Method Validation. The proposed method was vali-
dated for system suitability, linearity, LOD, LOQ, inter- and
intraday accuracies and precisions, robustness, ruggedness,
selectivity, and recovery for the assay of IMH by UPLC
according to the ICH guidelines [26].
3.2.1. System Suitability. System-suitability tests are an inte-
gral part of method development and are used to ensure ade-
quate performance of the chromatographic system. Choice of
retention time (Rt), tailing factor (𝑇), theoretical plates (𝑁),
and capacity factor (𝑘) was the major task while developing
the method and was evaluated for six replicate injections of
the drug at a concentration of 1 𝜇g/mL. The results presented
in Table 2 are within the acceptable limits.
3.2.2. Linearity and Limit of Detection and Quantitation. For
IMH, a linear calibration curve was obtained ranging from
0.2 to 3.0 𝜇g/mL. The slope, intercept, correlation coefficient
(𝑟2), standard deviation of slope, and intercept were
calculated from linear regression analysis. The correlation
coefficient is greater than 0.999. LOD, LOQ, and charac-
teristic parameters for regression equation observed during
the course of validation are given in Table 3. The calibration
curve for the proposed method is given in Figure 3.
3.2.3. Accuracy. The accuracy of the assay method was
evaluated in triplicate at three concentration levels in bulk
drug sample. The peak-area-based and retention-time-based
relative error values were <1%. The result obtained for the
evaluation of accuracy of the method is shown in Table 4.
3.2.4. Precision. The precision of the assay method was
evaluated by carrying out five independent assays.The%RSD
of assay of IMH determination was within the acceptable
limit of 1%. Intraday precision of the proposed method was
evaluated by assaying freshly prepared solutions in triplicates
at three different concentrations. Interday precision was
evaluated by using freshly prepared solution in triplicates on
three different days. These results are summarized in Table 5.
3.2.5. Robustness and Ruggedness. The robustness of an
analytical procedure is a measure of its capacity to remain
unaffected by small, but deliberate variations of the analytical
conditions. In all the deliberately varied chromatographic
conditions (flow rate, column temperature, mobile phase
composition, and pH variation), all of the analyte peaks
were adequately resolved, and the order elution remained
unchanged which indicates that the method is robust. In
method ruggedness, different columns (same lot), at differ-
ent days by different analysts, were performed. The results
obtained are shown in Tables 6 and 7.
3.2.6. Solution Stability andMobile Phase Stability. No signifi-
cant change in the chromatographic parameterswas observed
during the solution stability study. At the specified time
interval, the RSD (%) values for the IMH assay during
solution stability andmobile phase stability experiments were
within 1%. Stability of sample solution was established by
storage of sample solution at ambient temperature (25∘C) for
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Table 9: Results of determination of IMH in tablet and statistical comparison with the reference method.
Formulation brand name Nominal amount, mg/tab % IMH found
∗
± SD
Reference method Proposed method t-value F-value
Imipraminea 25mg 99.38 ± 0.30 99.95 ± 0.15 2.007 4.064
Depranilb 25mg 99.55 ± 0.22 100.04 ± 0.13 2.174 2.723
Marketed by aSun and bLa Pharma.
∗Mean value of five determinations.
Tabulated t-value at 95% confidence level is 2.78; tabulated F-value at 95% confidence level is 6.39.
Table 10: Results of recovery study by standard addition method.
Tablet studied IMH in tablet, 𝜇g/mL Pure IMH added, 𝜇g/mL Total found, 𝜇g/mL Pure IMH recovered∗ (% IMH ± SD)
Impramine
0.5 0.5 0.998 99.84 ± 0.09
0.5 1.0 1.502 100.22 ± 0.11
0.5 1.5 1.996 99.79 ± 0.25
Depranil
0.5 0.5 1.004 100.89 ± 0.04
0.5 1.0 1.495 99.54 ± 0.12
0.5 1.5 1.995 99.68 ± 0.23
∗Mean value of five determinations.
24 h. Sample solution was reanalyzed after 12 and 24 h time
intervals. The results from the solution stability and mobile
phase stability experiments confirmed that the standard
solutions of drug and solutions in the mobile phase were
stable at ambient temperature up to 24 h during the assay.The
results in Table 6 show no appreciable change in its system
suitability criteria.
3.2.7. Degradation Results. Stress testing provides evidence
on how the quality of a drug may be affected under the influ-
ence of different stress conditions. All forced degradation
samples were analyzed at 100 𝜇g/mL concentration level. The
method was capable of separating degradation products in
the presence of IMH; well-separated analyte and degrada-
tion peaks were obtained after all degradation experiments.
Acidic and basic stress led to 19.98 and 10.55% degradation,
respectively. About 13.13% degradation was observed under





was not observed in IMH samples under stress conditions
like neutral and photolytic stress conditions. IMH was also
observed to be thermally stable, and no decomposition was
seen on exposure of solid drug powder to dry heat at
80∘C or on expose to moist heat conditions (Figure 4). The
drug was found to be sensitive to acid, base, and oxidative
hydrolysis. IMH was found to be more stable under neutral,
photolytic (photostability chamber for 10 days), and thermal
(80∘C for 24 h) solid state conditions.This forced degradation
studies show that the method enables selective and specific
differentiation of the degradation peaks from the analyte
peak (Figure 4). Results from forced degradation studies are
presented in Table 8.
3.2.8. Selectivity of the Method. Selectivity is the ability of
the method to assess obviously the analyte in the presence
of components, which may be expected to be present. Typ-
ically, these might include degradants, matrix, and so forth.
Method selectivity was evaluated by injecting the mobile
phase, placebo blank, pure drug solution, and tablet extract.
Figures 5(a) and 5(b) demonstrate the selectivity experiments
with the chromatograms of tablet extracts. No peaks were
observed for mobile phase and placebo blank, and no extra
peaks were observed for tablet extracts.
3.2.9. Application of theMethod toDosage Forms. Thepresent
method was applied for the estimation of drugs and com-
mon excipients in the commercially available various dosage
forms. A 1 𝜇g/mL solution of tablets was prepared as per
“preparation of sample solution” and injected in triplicate
to the UPLC system. The validity of the proposed method
was ascertained by the statistical comparison of the results
obtained by the reported HPLC method [4] with the pro-
posed method by applying Student’s t-test for accuracy and
F-test for precision in some commercial formulations. The
results obtained are as shown in Table 9, and the t- and F-
values at 95% confidence level did not exceed the tabulated
values and this further confirms that there is no significant
difference between the reference and proposedmethods with
respect to accuracy and precision.
3.2.10. Recovery Study. Theaccuracy of the proposedmethod
was further ascertained by performing recovery studies via
standard addition technique. The sample is analysed for
the analyte of interest by adding a specified amount of
pure IMH to the sample, thus increasing its concentration.
The solutions were prepared by spiking preanalyzed tablet
with pure drug at three different levels and injected to
chromatographic column.The recovery of the known amount
of added analyte was computed. The percentage recovery of
IMH from pharmaceutical dosage forms ranged from 99.33
to 101.06%. The results presented in Table 10 reveal good
accuracy of the proposed method.
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4. Conclusions
The rapid isocratic RP-UPLC method developed for quan-
titative analysis of IMH in pharmaceutical dosage forms
is precise, accurate, linear, robust, and specific. This newly
developed UPLC method for IMH assay determination was
found to be capable of giving faster retention times, main-
taining good resolution; the method was completely showing
satisfactory data for all the parameters tested. This method
gives excellent performance in terms of sensitivity, speed, and
especially concerning in the decrease of time and solvent
consumption when compared to most of the reported chro-
matography/spectrophotometric methods (Table 1). Stress
testing is an important aspect of the drug development pro-
cess. The results of stress testing were undertaken according
to International Conference on Harmonization guidelines
reveal that it is a stability indicatingmethod suitable for rapid
analysis of imipramine hydrochloride in bulk drug and in
dosage forms.Hence, themethod developed is recommended
for the routine studies in the industries.
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